Clinical experience with cefamandole in pneumonia.

Abstract

The efficacy and patient acceptance of i.m. cefamandole 1 000 mg 8 h and 500 mg 8 h, were compared in the treatment of assumed community-acquired pneumonia in 59 hospitalized adult patients. Of 31 patients treated with 1 000 mg 8 h, 94% had a satisfactory clinical response with a 13% bacteriological failure rate. Of 28 patients treated with 500 mg 8 h, 89% had a satisfactory clinical response with a 60% bacteriological failure rate. The only side effect registered was pain at the injection site after doses of more than 1 000 mg. The pain could be eliminated by the addition of 0.5 ml of lidocaine to the drug solution before injection.

• Authors: K Mattson, O V Renkonen, A Kohvakka, H Likitalo
• Journal: Scandinavian journal of infectious diseases. Supplementum (Scand J Infect Dis Suppl) Vol. suppl 25 Pg. 103-6 ( 1980) ISSN: 0300-8878 [Print] England
• PMID: 7010534 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Cephalosporins
• Cefamandole

Topics

• Adult
• Aged
• Bronchopneumonia (drug therapy)
• Cefamandole (therapeutic use)
• Cephalosporins (therapeutic use)
• Clinical Trials as Topic
• Female
• Haemophilus influenzae (isolation & purification)
• Humans
• Male
• Middle Aged
• Pleuropneumonia (drug therapy)
• Pneumonia (drug therapy)
• Pneumonia, Pneumococcal (drug therapy)
• Proteus mirabilis (isolation & purification)
• Streptococcus pneumoniae (isolation & purification)